United Therapeutics (UTHR) CFO sells 10K shares post option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales. On June 15, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share and converted those options into stock.
On the same date, he sold 10,000 shares of United Therapeutics common stock in multiple open-market transactions, at weighted average prices generally in the low-to-mid $500s per share, as detailed by price ranges in the footnotes. After these transactions, he directly owned 28,876 shares of common stock. The filing states that the option exercise and subsequent sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($5,491,742)
Net Sell
16 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.49M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $117.76 | $1.18M |
| Sale | Common Stock | 121 | $538.5233 | $65K |
| Sale | Common Stock | 74 | $539.4576 | $40K |
| Sale | Common Stock | 45 | $540.638 | $24K |
| Sale | Common Stock | 240 | $541.6117 | $130K |
| Sale | Common Stock | 560 | $543.5046 | $304K |
| Sale | Common Stock | 855 | $545.6344 | $467K |
| Sale | Common Stock | 504 | $546.5354 | $275K |
| Sale | Common Stock | 465 | $547.7661 | $255K |
| Sale | Common Stock | 1,616 | $548.6391 | $887K |
| Sale | Common Stock | 800 | $549.8704 | $440K |
| Sale | Common Stock | 2,200 | $550.8909 | $1.21M |
| Sale | Common Stock | 1,144 | $551.9074 | $631K |
| Sale | Common Stock | 778 | $553.0989 | $430K |
| Sale | Common Stock | 598 | $553.7629 | $331K |
Holdings After Transaction:
Stock Option — 0 shares (Direct, null);
Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $548.27 to $549.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $549.34 to $550.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $550.36 to $551.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $551.40 to $552.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $552.42 to $553.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $553.45 to $554.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $537.91 to $538.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $538.91 to $539.865. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.96 to $540.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $541.57 to $541.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $542.99 to $543.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $545.06 to $546.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $546.16 to $547.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $547.25 to $548.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Option shares exercised: 10,000 shares
Option exercise price: $117.76 per share
+4 more
7 metrics
Shares sold
10,000 shares
Open-market sales of common stock on June 15, 2026
Option shares exercised
10,000 shares
Stock options exercised into common stock on June 15, 2026
Option exercise price
$117.76 per share
Exercise price for 10,000 stock options
Post-transaction holdings
28,876 shares
Common stock directly owned after reported transactions
Highest weighted average sale price
$553.76 per share
One of the reported weighted average sale prices for common stock
Lowest weighted average sale price
$538.52 per share
One of the reported weighted average sale prices for common stock
Option expiration date
March 15, 2027
Expiration for the exercised stock option grant
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock options, Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did United Therapeutics (UTHR) report for CFO James Edgemond?
United Therapeutics CFO James Edgemond exercised 10,000 stock options and sold 10,000 shares. The Form 4 shows a same-day option exercise and open-market sales of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.
What stock options did the United Therapeutics (UTHR) CFO exercise in this Form 4?
He exercised stock options covering 10,000 shares of common stock at $117.76 per share. These options, originally exercisable from March 15, 2023 and expiring March 15, 2027, were fully exercised and converted into common shares.
What does the United Therapeutics (UTHR) Form 4 say about trade pricing details?
The Form 4 notes that many sales were executed in multiple trades within specified price ranges. For each such sale, the reported price is a weighted average, and the insider undertakes to provide full trade details upon request to regulators or shareholders.